

FISCAL NOTE

November 4, 2021

| Bill No: | HB 293 | Printer's No: | 259 | Sponsor: | Oberlander (R) |
|----------|--------|---------------|-----|----------|----------------|

COST / (SAVINGS)

| Fund (s) | 2021-22 | 2022-23 |
|---------------|-----------------|-----------------|
| General Fund | \$3.173 million | \$3.173 million |
| Federal Funds | \$6.400 million | \$6.400 million |

SUMMARY: This bill adds anti-obesity drugs to the Medical Assistance program.

ANALYSIS: HB 293 establishes anti-obesity drugs approved by the federal government shall be considered a compensable item under the Medical Assistance (MA) program.

FISCAL IMPACT: Adding anti-obesity drugs as a compensable item under MA would carry an estimated annual cost of \$9.573 million (\$3.173 million in state funds).

| Total MA | Obesity Rate | Potential MA | Estimated | Cost per | Annual Cost |
|-------------|--------------|--------------|------------------|----------|--|
| Population | | participants | utilization rate | patient | |
| 1.9 million | 31.6 percent | 600,449 | 1 percent | \$1,600 | \$9.573 million (\$3.173 million in state funds) |